SalioGen Therapeutics hit by layoffs, as gene-editing biotechs continue to struggle

SalioGen Therapeutics, a company that raised $135 million to develop a new gene-editing technology, has instituted widespread layoffs and is scaling back its ambitions, according to a person familiar with the situation and employee posts on social media.

It is the latest in a series of retrenchments by high-profile gene-editing companies. A spokesperson for SalioGen declined to comment.

Launched in 2021, SalioGen was among a group of new startups developing technology for inserting full-length genes into patients — a feat that can’t readily be accomplished with older approaches based on the gene-editing technology CRISPR.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Oculis touts Phase 2 results in dry eye disease, but most data aren’t statistically significant

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 11, 2024

A Misnomer in Mushrooms: The Jedi Mind Fuck Strain | Psychedelic Spotlight

Step into the world of psychedelic mushrooms, where legends and lore often intertwine with reality. Among the fascinating array of Psilocybe cubensis varieties, one strain

June 15, 2023

Pharmalittle: We’re reading about a probe of Pfizer and Lilly telehealth, pharma exec donations, and more

Top of the morning to you and a fine one it is. Blue skies, cool breezes, and plenty of chirping birds are enveloping the comfy

October 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.